4D Molecular (NASDAQ: FDMT) awards 217,000 stock options to CLO

Rhea-AI Filing Summary

4D Molecular Therapeutics reported a stock option grant to Chief Legal Officer Scott Bizily. The award covers 217,000 options for common stock at an exercise price of $9.88 per share and expires on March 24, 2036.

The options vest in equal monthly installments over four years, with 1/48th of the underlying shares vesting on each monthly anniversary of March 25, 2026, so long as Bizily remains a service provider. This is a compensation-related equity grant, not an open-market share purchase or sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bizily Scott

(Last) (First) (Middle)

C/O 4D MOLECULAR THERAPEUTICS, INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.88	03/25/2026		A		217,000		(1)	03/24/2036	Common Stock	217,000	$0	217,000	D

Explanation of Responses:

1. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 25, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

	/s/ Scott Bizily	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did FDMT’s Chief Legal Officer report in this Form 4 filing?

The filing reports a grant of 217,000 stock options to Chief Legal Officer Scott Bizily. These options are part of equity compensation and do not represent an open-market share purchase or sale. They provide the right to buy common stock at a set price.

What is the exercise price and term of the new FDMT stock options?

The granted options have an exercise price of $9.88 per share and expire on March 24, 2036. This means the holder can buy common shares at $9.88 any time after vesting and before expiration, subject to remaining employed or serving the company.

How do the 4D Molecular (FDMT) options granted to the CLO vest?

The options vest in 48 equal monthly installments starting on March 25, 2026. Each month, 1/48th of the 217,000 underlying shares becomes exercisable, so the award is fully vested on the fourth anniversary, if the recipient continues as a service provider.

Is the FDMT Form 4 transaction a stock purchase or sale on the market?

No, the Form 4 reflects a compensation-related option grant, not an open-market stock purchase or sale. The reporting person received derivative securities (options) at no cash cost, which may later be exercised to acquire common shares if conditions are met.

How many FDMT shares underlie the Chief Legal Officer’s new option grant?

The award covers 217,000 underlying shares of common stock. These shares are not issued immediately; they become purchasable over time as the options vest, assuming the Chief Legal Officer continues providing services to 4D Molecular Therapeutics throughout the vesting period.